Cardiac toxicity associated with pharmacokinetic drug-drug interaction between crizotinib and sofosbuvir/velpatasvir : A case report
© 2023 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society..
This case report describes a pharmacokinetic drug-drug interaction between crizotinib, a tyrosine kinase inhibitor, and sofosbuvir/velpatasvir, a direct-acting antiviral drug, leading to cardiac toxicity. A 75-year-old man, with no cardiovascular history but a diagnosis of metastatic nonsmall cell lung cancer with mesenchymal-epithelial transition exon-14 deletion and hepatitis C virus infection genotype 1A, received both crizotinib and sofosbuvir/velpatasvir. Crizotinib was well tolerated, but 1 week after sofosbuvir/velpatasvir initiation, the patient experienced bilateral lower-limb oedema and class III New York Heart Association dyspnoea. We assumed that increased exposure to crizotinib could account for this cardiac toxicity. Drug causality was probable according to the Naranjo scale. We hypothesized a reciprocal interaction between crizotinib and velpatasvir, mediated by both cytochrome 3A4 (CYP3A4) and P-glycoprotein (P-gp). Clinicians should be aware of the risk of drug-drug interactions between direct-acting antiviral agents that inhibit CYP3A4 (glecaprevir) and/or P-gp (voxilaprevir, velpatasvir) and anticancer tyrosine kinase inhibitors that are mostly CYP3A4 and/or P-gp substrates (gefitinib, afatinib, erlotinib, crizotinib, ceritinib, lorlatinib, brigatinib, capmatinib etc.).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:89 |
|---|---|
| Enthalten in: |
British journal of clinical pharmacology - 89(2023), 4 vom: 28. Apr., Seite 1486-1490 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Monribot, Anthia [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.03.2023 Date Revised 29.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bcp.15674 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352203951 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352203951 | ||
| 003 | DE-627 | ||
| 005 | 20231226053159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bcp.15674 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1173.xml |
| 035 | |a (DE-627)NLM352203951 | ||
| 035 | |a (NLM)36709977 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Monribot, Anthia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiac toxicity associated with pharmacokinetic drug-drug interaction between crizotinib and sofosbuvir/velpatasvir |b A case report |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2023 | ||
| 500 | |a Date Revised 29.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. | ||
| 520 | |a This case report describes a pharmacokinetic drug-drug interaction between crizotinib, a tyrosine kinase inhibitor, and sofosbuvir/velpatasvir, a direct-acting antiviral drug, leading to cardiac toxicity. A 75-year-old man, with no cardiovascular history but a diagnosis of metastatic nonsmall cell lung cancer with mesenchymal-epithelial transition exon-14 deletion and hepatitis C virus infection genotype 1A, received both crizotinib and sofosbuvir/velpatasvir. Crizotinib was well tolerated, but 1 week after sofosbuvir/velpatasvir initiation, the patient experienced bilateral lower-limb oedema and class III New York Heart Association dyspnoea. We assumed that increased exposure to crizotinib could account for this cardiac toxicity. Drug causality was probable according to the Naranjo scale. We hypothesized a reciprocal interaction between crizotinib and velpatasvir, mediated by both cytochrome 3A4 (CYP3A4) and P-glycoprotein (P-gp). Clinicians should be aware of the risk of drug-drug interactions between direct-acting antiviral agents that inhibit CYP3A4 (glecaprevir) and/or P-gp (voxilaprevir, velpatasvir) and anticancer tyrosine kinase inhibitors that are mostly CYP3A4 and/or P-gp substrates (gefitinib, afatinib, erlotinib, crizotinib, ceritinib, lorlatinib, brigatinib, capmatinib etc.) | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a P-glycoprotein | |
| 650 | 4 | |a anticancer drugs | |
| 650 | 4 | |a cytochrome P450 enzymes | |
| 650 | 4 | |a drug interactions | |
| 650 | 4 | |a therapeutic drug monitoring | |
| 650 | 7 | |a Sofosbuvir |2 NLM | |
| 650 | 7 | |a WJ6CA3ZU8B |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a velpatasvir |2 NLM | |
| 650 | 7 | |a KCU0C7RS7Z |2 NLM | |
| 650 | 7 | |a Crizotinib |2 NLM | |
| 650 | 7 | |a 53AH36668S |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 CYP3A |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 650 | 7 | |a Macrocyclic Compounds |2 NLM | |
| 700 | 1 | |a Huillard, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Khoudour, Nihel |e verfasserin |4 aut | |
| 700 | 1 | |a Préta, Laure-Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Blanchet, Benoit |e verfasserin |4 aut | |
| 700 | 1 | |a Cabanes, Laure |e verfasserin |4 aut | |
| 700 | 1 | |a Batista, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Pallet, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Chouchana, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Goldwasser, François |e verfasserin |4 aut | |
| 700 | 1 | |a Sogni, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas-Schoemann, Audrey |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d 1974 |g 89(2023), 4 vom: 28. Apr., Seite 1486-1490 |w (DE-627)NLM000097799 |x 1365-2125 |7 nnns |
| 773 | 1 | 8 | |g volume:89 |g year:2023 |g number:4 |g day:28 |g month:04 |g pages:1486-1490 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bcp.15674 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 89 |j 2023 |e 4 |b 28 |c 04 |h 1486-1490 | ||